Renovaro Biosciences Inc.
Elango Kathirvel is an accomplished professional with extensive experience in analytical and product development within the biopharmaceutical industry. Currently serving as the Director of Analytical Development at Renovaro Biosciences Inc., Elango leads the development of Dendritic Cell Therapy for Pancreatic Cancer, following a role as Principal Scientist focusing on the same therapy. Prior to Renovaro, Elango held positions at Nitto Avecia Pharma Services and Pharmavite, emphasizing quality control in pharmaceutical and supplement manufacturing. With a solid foundation in research, Elango worked as a Research Scientist at UC Irvine, overseeing projects related to diabetes and liver disease, and at the Naval Medical Research Center, concentrating on DNA vaccine development. Elango holds a PhD in Biology from the University of Madras, awarded in 2004.
This person is not in any teams
Renovaro Biosciences Inc.
Renovaro Biosciences, Inc. is a biotechnology company committed to developing advanced allogenic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as HIV and Hepatitis B virus (HBV) infection. F